Navigation Links
Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million

FARMINGDALE, N.Y., Aug. 5 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the sale of its Labcaire subsidiary to PuriCore International Limited ("PuriCore") for a total purchase price of up to $5.6 million. Misonix received $3,600,000 at closing and a promissory note in the principal amount of $1,000,000, payable in equal installments of $250,000 on the next four anniversaries of the closing. Misonix will also receive a commission paid on sales for the period commencing on the date of closing and ending on December 31, 2013 of 8% of the pass through Automated Endoscope Reprocessing ("AER") and Drying Cabinet products, and 5% of license fees from any chemical licenses marketed by Labcaire directly associated with sales of AER's, specifically for the disinfection of the endoscope. The aggregate commission payable to Misonix is subject to a maximum payment of $1,000,000.

The financial position of Labcaire as of the fiscal year ended June 30, 2009, which is currently unaudited, includes revenues of $14 million and a net loss of $7,000 as compared to revenues of $13.6 million and a net loss of $389,000 for the fiscal year ended June 30, 2008 which was audited as part of the overall Misonix reported results for that period.

Michael A. McManus, Jr., President and Chief Executive Officer stated, "We are very pleased to have completed the transaction with PuriCore. Our strategy has been to create a medical device company that has proprietary, innovative, high margin products that utilize ultrasound as the core technology and we believe the completion of this transaction further supports that goal. Additionally, the cash payment of $3.6 million plus future payments of up to $2 million will give Misonix a solid balance sheet with sufficient cash reserves and no long-term debt. We believe this is extremely important in our current economic environment. We are also confident that Labcaire employees will be part of a combination that will be a stronger organization in the United Kingdom Endoscopic Reprocessing market."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Receives First Award for Forensic Equipment in China
2. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
3. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
4. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
5. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
6. Misonix Announces Participation in Annual Diabetic Foot Global Conference
7. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
8. Misonix Announces New HIFU Distribution Agreement For Portugal
9. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
10. Misonix Announces New Distribution Agreement for Portugal
11. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
Post Your Comments:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding them ... a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to provide ... need to turn on a light when taking medication during the night, allowing the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)...   Divoti USA will engrave and process ... of the latest FDA requirements, which stipulates new criteria regarding medical ... need of Medical ID jewelry such as Medical ID Bracelets, can ... in terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
Breaking Medicine Technology: